AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +65

AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

📊 AbbVie presented Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab achieved a median progression-free survival of 6.4 years versus 3.2 years for the comparator in previously untreated chronic lymphocytic leukemia.

🇪🇺 The European Commission authorized an expanded label for Venclyxto on May 29, 2026, including use with acalabrutinib or ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia in the EU and EEA.

💊 The FDA approved DECNUPAZ (pivekimab sunirine-pvzy) on May 27, 2026, for treating adult patients with BPDCN based on Phase 1/2 CADENZA trial data showing a 69.7% composite complete response rate in newly diagnosed patients.

📈 The fixed-duration regimens support current standards of care and provide additional targeted oral medication options in the first-line setting, including potential for time off treatment.

🔬 AbbVie's oncology portfolio expands with approvals in chronic lymphocytic leukemia and ultra-rare hematologic malignancies, reinforcing its therapeutic focus.

Bullish Signals
  • AbbVie received FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) for treating adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.
  • The European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib or ibrutinib for previously untreated chronic lymphocytic leukemia, extending availability across the EU and EEA.
  • Phase 3 CLL14 trial data demonstrated a significant improvement in progression-free survival (6.4 years vs. 3.2 years) for venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab after a median follow-up of 9.2 years.
  • The new fixed-duration combination regimens support current standards of care and offer patients the potential for time off treatment, enhancing patient convenience and quality of life.
Full Analysis
AbbVie Inc. (NYSE: ABBV) presented new Phase 3 data from the CLL14 trial at the European Hematology Association 2026 Congress in Stockholm, showing that a fixed-duration combination of venetoclax and obinutuzumab significantly improved progression-free survival compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. Following a median follow-up of 9.2 years, the trial demonstrated a median progression-free survival of 6.4 years for the venetoclax and obinutuzumab regimen versus 3.2 years for the comparator group. This data supports the expanded European Commission authorization granted on May 29, 2026, allowing Venclyxto in combination with acalabrutinib or ibrutinib for adult patients. Additionally, AbbVie received FDA approval on May 27, 2026, for DECNUPAZ (pivekimab sunirine-pvzy) to treat adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy. Clinical data from the Phase 1/2 CADENZA trial showed a composite complete response rate of 69.7% in newly diagnosed patients and 15.7% in relapsed or refractory cases. These regulatory approvals and positive clinical outcomes reinforce AbbVie's position in oncology, offering targeted oral medication options with potential for time off treatment. The company continues to research, develop, manufacture, and commercialize medicines worldwide, though the article notes a separate editorial view favoring AI stocks over ABBV.